Vitruvias Therapeutics and Sunny Pharmtech have received approval from the Food and Drug Administration (FDA) to market a generic equivalent to Amicar (Akorn), an inhibitor of fibrinolysis.
Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.
Aminocaproic Acid Tablets will be available in 500mg and 1000mg strengths.
For more information visit vitruvias.com.
This article originally appeared on MPR